BRAF and colorectal carcinoma: Also on this parameter, cetuximab alone (100 μg/ml) was found to be moderately effective only in CRC cell lines with wild-type KRAS, BRAF and PIK3CA genes (inhibition of tube formation index, 22% and 20% on CACO-2 and SW48 cells, respectively).